SCIENTIFIC PROGRAMME
SESSION I
HOW I TREAT
SMOLDERING MYELOMA
(SMM)
SESSION II
HOW I TREAT NEWLY
DIAGNOSED MULTIPLE
MYELOMA
SESSION III
FROM RISK
STRATIFICATION TO
RISK-BASED THERAPY?
DEBATE 1
SHOULD WE USE MRD
TESTING TO DETERMINE
THERAPY IN MULTIPLE
MYELOMA?
DEBATE 2
IS THERE A FUTURE ROLE
OF AUTOLOGOUS STEM
CELL TRANSPLANTATION?
SESSION IV
HOW I TREAT RELAPSED
MULTIPLE MYELOMA
DEBATE 3
SHOULD EVERY PATIENT
RECEIVE DARATUMUMAB
IN FIRST LINE?
ROUNDTABLE
MULTIPLE MYELOMA
FROM THE PERSPECTIVE
OF FDA/EMEA AND
FOUNDATIONS
SESSION V
YOU CAN’T BE IMMUNE
FOR IMMUNE THERAPY
ANYMORE
SESSION VI
OTHER PLASMA CELL
DYSCRASIAS
KEYNOTE LECTURES
THE FUTURE OF
MULTIPLE MYELOMA
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
ABSTRACTS SELECTED
AS POSTERS
DARATUMUMAB SC+SOC IN MM ACROSS LINES OF THERAPY IN PHASE 2 PLEIADES STUDY:
DISCLOSURES POSTER 47
INITIAL RESULTS FOR DARATUMUMAB SC+CARFILZOMIB/DEXAMETHASONE AND
UPDATED RESULTS FOR DARATUMUMAB SC+BORTEZOMIB/MELPHALAN/PREDNISONE OR
LENALIDOMIDE/DEXAMETHASONE
Cyrille Touzeau1, Ajai Chari2, Mathias Hänel3, Albert Oriol4, Paula Rodriguez-Otero5, Helen McCarthy6,
Kenshi Suzuki7, Vania Hungria8, Anna Sureda Balari9, Lauriane Clement-Filliatre10, Cyrille Hulin11, Hila
Magen12, Shinsuke Iida13, Vladimir Maisnar14, Lionel Karlin15, Ludek Pour16, Philippe Moreau1, Shiyi
Yang17, Michele Kosh17, Maria Delioukina17, Christoph Heuck17 and Hartmut Goldschmidt18
(1)Hematology, University Hospital Hôtel-Dieu, Nantes, France
(2)Icahn School of Medicine at Mount Sinai, New York
(3)Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany
(4)Institut Català d’Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
(5)Clínica Universidad de Navarra, Pamplona, Spain
(6)Royal Bournemouth Hospital, Bournemouth, United Kingdom
(7)Japanese Red Cross Medical Center, Department of Hematology, Tokyo, Japan
(8)Clinica Medica São Germano, São Paulo, Brazil
(9)Hematology Department, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona,
Barcelona, Spain
(10)Department of Hematology, CHRU Nancy Brabois, Vandoeuvre les Nancy, France
(11)Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France
(12)Department of Hematology Chaim Sheba Medical Center, Ramat-Gan, Sackler Faculty of Medicine,
Tel Aviv University, Tel Aviv, Israel
(13)Department of Hematology and Oncology, Nagoya City University Institute of Medical and
Pharmaceutical Sciences, Nagoya, Japan
(14)4th Department of Medicine - Haematology, Charles University Hospital, Hradec Králové, Czech
Republic
(15)Department of Hematology, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Pierre-Bénite,
France
(16)University Hospital Brno, Brno, Czech Republic
(17)Janssen Research & Development, LLC, Spring House, PA, United States of America
(18)University Clinic Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT),
Heidelberg, Germany
Objectives: Daratumumab, a human IgGκ CD38-targeting monoclonal antibody, is approved for
intravenous (IV) infusion across lines of therapy for multiple myeloma (MM). Subcutaneous (SC)
daratumumab (1800 mg, coformulated with recombinant human hyaluronidase PH20) was assessed
in COLUMBA (NCT03277105) and approved. Advantages of daratumumab SC include reduced
administration time (3-5 minutes) and lower rates of infusion-related reactions (IRRs). The phase 2
PLEIADES study evaluated the safety and efficacy of daratumumab SC combined with standard-of-care
(SoC) regimens, including carfilzomib/dexamethasone (D-Kd) and lenalidomide/dexamethasone (D-Rd)
for relapsed/refractory MM (RRMM) and bortezomib/melphalan/prednisone (D-VMP) for
transplant-ineligible newly diagnosed MM (TIE NDMM). In the primary analysis, D-Rd and D-VMP
demonstrated clinical activity and safety comparable to daratumumab IV regimens, with low rates of
IRRs. The primary analysis for D-Kd and updated results for D-Rd and D-VMP cohorts are presented.
Methods: Patients with RRMM with 1 prior line of therapy (including 2 consecutive cycles of
lenalidomide) received 28-day cycles of daratumumab SC (Cycles 1-2, QW; 3-6, Q2W; 7+, Q4W) with
Kd (K: 70 mg/m2 IV on Days 1, 8 and 15 20 mg/m2 on Cycle 1 Day 1; d: 40 mg IV/oral QW). Patients